Nagpur: The use of Montelukast asthma drugs, debated for Covid-19 management by Yavatmal psychiatrists, has been given an innovation patent in Australia.
Dr.
Prashant Chakkarwar, a psychiatrist who trained in Yavatmal, has also treated Covid patients based on the basic MBB degree.
Dr.
Chakkarwar has pushed the case for Montelukast as a cheap alternative treatment for shortness of breath and freezing due to Covid-19 infection.
He has made a representation before the Committee of the Indian Medical Research Council (ICMR) during the first wave.
It was part of a number of other suggestions made at that time.
However, doctors also clarify that gaining patents does not mean that this has been officially included as a treatment by the government in India.
The patent only gave him a legal right for the use of Montelukast as a covid-related complications.
“If there is a pharmaceutical company marketing drugs with the same indication, I can enforce my intellectual property rights, even though I don’t intend to do it,” he said.
Dr.
Chakkarwar said the goal of securing a patent was only to get authenticity in his theory.
There are drug clinical test reports carried out elsewhere in this country, he said.
According to the theory of Dr.
Chakkarwar, Montelukast is a leukotriene receptor antagonist and is used against lung inflammation during asthma treatment.
In other words, it acts against chemicals in the blood that causes lung and injury inflammation.
Even in Covid, inflammation of the lungs occur due to cytokine storms, which is basically an excessive immunological response of the body.
He said even because there was no study that confirmed the involvement of Leukotrien during the cytokine storm, it had become his experience that Montelukast worked when given to Covid patients.
He also claimed that the drug acted against hyper coagulation of blood (freezing) in covid patients.
Small clots in the bloodstream formed by Post Covid also ate life due to heart attack and brain stroke.
Even when depression is a known side effect of Montelukast, it can occur after long-term consumption and not for a short period during covid treatment, claimed Dr.
Chakkarwar.
Dr.
Chakkarwar said the theory of Montelukast was originally a hypothesis.
However, the drug was also given around 300 covid patients during treatment.
There are no clinical trials taken because this must be done at the institutional level, he said.
However, Dr.
Chakkarwar’s article was published in the journal evidence-based treatment and health care, after that the application was submitted in Australia on July 26, 2021, and the patent innovation was given on December 24, 2021.
He had shared a patent certificate with TOI.
In India, the same effort was slowed by red ribbons, the psychiatrist said.